These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27515131)

  • 1. The chemical class of quinazoline compounds provides a core structure for the design of anticytomegaloviral kinase inhibitors.
    Hutterer C; Hamilton S; Steingruber M; Zeitträger I; Bahsi H; Thuma N; Naing Z; Örfi Z; Örfi L; Socher E; Sticht H; Rawlinson W; Chou S; Haupt VJ; Marschall M
    Antiviral Res; 2016 Oct; 134():130-143. PubMed ID: 27515131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity.
    Herget T; Freitag M; Morbitzer M; Kupfer R; Stamminger T; Marschall M
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4154-62. PubMed ID: 15504835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
    Piret J; Boivin G
    Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonistic Relationship between Human Cytomegalovirus pUL27 and pUL97 Activities during Infection.
    Bigley TM; Reitsma JM; Terhune SS
    J Virol; 2015 Oct; 89(20):10230-46. PubMed ID: 26223645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel cytomegalovirus-inhibitory compounds of the class pyrrolopyridines show a complex pattern of target binding that suggests an unusual mechanism of antiviral activity.
    Hahn F; Hutterer C; Henry C; Hamilton ST; Strojan H; Kraut A; Schulte U; Schütz M; Kohrt S; Wangen C; Pfizer J; Couté Y; Rawlinson WD; Strobl S; Marschall M
    Antiviral Res; 2018 Nov; 159():84-94. PubMed ID: 30268914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97.
    Marschall M; Stein-Gerlach M; Freitag M; Kupfer R; van den Bogaard M; Stamminger T
    J Gen Virol; 2001 Jun; 82(Pt 6):1439-1450. PubMed ID: 11369889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral therapy.
    Marschall M; Stein-Gerlach M; Freitag M; Kupfer R; van den Bogaard M; Stamminger T
    J Gen Virol; 2002 May; 83(Pt 5):1013-1023. PubMed ID: 11961255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility.
    Webel R; Hakki M; Prichard MN; Rawlinson WD; Marschall M; Chou S
    J Virol; 2014 May; 88(9):4776-85. PubMed ID: 24522923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo.
    Schleiss M; Eickhoff J; Auerochs S; Leis M; Abele S; Rechter S; Choi Y; Anderson J; Scott G; Rawlinson W; Michel D; Ensminger S; Klebl B; Stamminger T; Marschall M
    Antiviral Res; 2008 Jul; 79(1):49-61. PubMed ID: 18329738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the Cytomegalovirus Cyclin-Dependent Kinase Ortholog pUL97 as a Multifaceted Regulator and an Antiviral Drug Target.
    Marschall M; Schütz M; Wild M; Socher E; Wangen C; Dhotre K; Rawlinson WD; Sticht H
    Cells; 2024 Aug; 13(16):. PubMed ID: 39195228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathways.
    Komatsu TE; Pikis A; Naeger LK; Harrington PR
    Antiviral Res; 2014 Jan; 101():12-25. PubMed ID: 24184129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinatorial Drug Treatments Reveal Promising Anticytomegaloviral Profiles for Clinically Relevant Pharmaceutical Kinase Inhibitors (PKIs).
    Wild M; Kicuntod J; Seyler L; Wangen C; Bertzbach LD; Conradie AM; Kaufer BB; Wagner S; Michel D; Eickhoff J; Tsogoeva SB; Bäuerle T; Hahn F; Marschall M
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246.
    Lischka P; Hewlett G; Wunberg T; Baumeister J; Paulsen D; Goldner T; Ruebsamen-Schaeff H; Zimmermann H
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1290-7. PubMed ID: 20047911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral inhibition targeting the HCMV kinase pUL97 requires pUL27-dependent degradation of Tip60 acetyltransferase and cell-cycle arrest.
    Reitsma JM; Savaryn JP; Faust K; Sato H; Halligan BD; Terhune SS
    Cell Host Microbe; 2011 Feb; 9(2):103-14. PubMed ID: 21320693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and characterization of novel quinazoline type inhibitors for mutant and wild-type EGFR and RICK kinases.
    Breza N; Pato J; Orfi L; Hegymegi-Barakonyi B; Banhegyi P; Varkondi E; Borbely G; Petak I; Keri G
    J Recept Signal Transduct Res; 2008; 28(4):361-73. PubMed ID: 18702009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin-Dependent Kinases (CDKs) and the Human Cytomegalovirus-Encoded CDK Ortholog pUL97 Represent Highly Attractive Targets for Synergistic Drug Combinations.
    Wild M; Hahn F; Brückner N; Schütz M; Wangen C; Wagner S; Sommerer M; Strobl S; Marschall M
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase.
    Zimmermann A; Wilts H; Lenhardt M; Hahn M; Mertens T
    Antiviral Res; 2000 Oct; 48(1):49-60. PubMed ID: 11080540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of dual-specificity tyrosine phosphorylation-regulated kinases (DYRK) exert a strong anti-herpesviral activity.
    Hutterer C; Milbradt J; Hamilton S; Zaja M; Leban J; Henry C; Vitt D; Steingruber M; Sonntag E; Zeitträger I; Bahsi H; Stamminger T; Rawlinson W; Strobl S; Marschall M
    Antiviral Res; 2017 Jul; 143():113-121. PubMed ID: 28400201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An in silico-designed flavone derivative, 6-fluoro-4'-hydroxy-3',5'-dimetoxyflavone, has a greater anti-human cytomegalovirus effect than ganciclovir in infected cells.
    Fujimoto KJ; Nema D; Ninomiya M; Koketsu M; Sadanari H; Takemoto M; Daikoku T; Murayama T
    Antiviral Res; 2018 Jun; 154():10-16. PubMed ID: 29559264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication.
    Wildum S; Zimmermann H; Lischka P
    Antimicrob Agents Chemother; 2015; 59(6):3140-8. PubMed ID: 25779572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.